Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Jun Li(Memorial Sloan Kettering Cancer Center), Mercedes A. Duran Paez(Memorial Sloan Kettering Cancer Center), Ninjit Dhanota(Memorial Sloan Kettering Cancer Center), Walid K. Chatila(Memorial Sloan Kettering Cancer Center), Sarah E. Bettigole(Inzen Therapeutics (United States)), John Kwon(Memorial Sloan Kettering Cancer Center), Roshan K. Sriram(Cornell University), Matthew P. Humphries(Queen's University Belfast), Manuel Salto‐Tellez(Queen's University Belfast), Jacqueline A. James(Queen's University Belfast), Matthew G. Hanna(Memorial Sloan Kettering Cancer Center), Johannes C. Melms(Columbia University Irving Medical Center), Sreeram Vallabhaneni(Center for Systems Biology), Kevin Litchfield(The Francis Crick Institute), Ieva Usaite(The Francis Crick Institute), Dhruva Biswas(The Francis Crick Institute), Rohan Bareja(Cornell University), Hao Wei Li(Center for Translational Molecular Medicine), M. Laura Martín(Cornell University), Princesca Dorsaint(Cornell University), Julie‐Ann Cavallo(Memorial Sloan Kettering Cancer Center), Li Peng(Memorial Sloan Kettering Cancer Center), Chantal Pauli(University Hospital of Zurich), Lee Gottesdiener(Memorial Sloan Kettering Cancer Center), Benjamin J. DiPardo(University of California, Los Angeles), Travis J. Hollmann(University of Oxford), Taha Merghoub(Memorial Sloan Kettering Cancer Center), Hannah Y. Wen(Memorial Sloan Kettering Cancer Center), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center), Nadeem Riaz(Memorial Sloan Kettering Cancer Center), Shinsan M. Su(Inzen Therapeutics (United States)), Anusha Kalbasi(Comprehensive Blood & Cancer Center), Neil Vasan(Memorial Sloan Kettering Cancer Center), Simon N. Powell(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center), Olivier Elemento(Cornell University), Charles Swanton(The Francis Crick Institute), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center), Eileen E. Parkes(Queen's University Belfast), Benjamin Izar(Columbia University Irving Medical Center), Samuel F. Bakhoum(Memorial Sloan Kettering Cancer Center)
Cancer Discovery
December 28, 2020
Cited by 276Open Access
Full Text

Abstract

Abstract Cytosolic DNA is characteristic of chromosomally unstable metastatic cancer cells, resulting in constitutive activation of the cGAS–STING innate immune pathway. How tumors co-opt inflammatory signaling while evading immune surveillance remains unknown. Here, we show that the ectonucleotidase ENPP1 promotes metastasis by selectively degrading extracellular cGAMP, an immune-stimulatory metabolite whose breakdown products include the immune suppressor adenosine. ENPP1 loss suppresses metastasis, restores tumor immune infiltration, and potentiates response to immune checkpoint blockade in a manner dependent on tumor cGAS and host STING. Conversely, overexpression of wild-type ENPP1, but not an enzymatically weakened mutant, promotes migration and metastasis, in part through the generation of extracellular adenosine, and renders otherwise sensitive tumors completely resistant to immunotherapy. In human cancers, ENPP1 expression correlates with reduced immune cell infiltration, increased metastasis, and resistance to anti–PD-1/PD-L1 treatment. Thus, cGAMP hydrolysis by ENPP1 enables chromosomally unstable tumors to transmute cGAS activation into an immune-suppressive pathway. Significance: Chromosomal instability promotes metastasis by generating chronic tumor inflammation. ENPP1 facilitates metastasis and enables tumor cells to tolerate inflammation by hydrolyzing the immunotransmitter cGAMP, preventing its transfer from cancer cells to immune cells. This article is highlighted in the In This Issue feature, p. 995


Related Papers

No related papers found

Powered by citation graph analysis